Keywords: merck, kgaa, stimuvax, shows, mild, aes, up
Merck KGaA's Stimuvax shows mild AEs with up to 8.2 years of use
Article | 01 June 2009
Extended follow-up data from a randomized Phase IIb study of patients with inoperable advanced non-small cell lung cancer receiving Merck ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
